
Stock investments ranging from Biotech, Pharmaceutical, and Medical Devices in the Healthcare Sector. Covering Clinical Trial recommendations and FDA Approvals.
Showing posts with label Gamma-Hydroxybutyric acid. Show all posts
Showing posts with label Gamma-Hydroxybutyric acid. Show all posts
8/20/10
Jazz Pharma rejected for Fibramyalgia Drug by FDA vote 20-2

Labels:
Biotechnology and Pharmaceuticals,
FDA,
Gamma-Hydroxybutyric acid,
Jazz Pharmaceuticals,
Top Performing BioPharma Stocks,
Xyrem
8/18/10
FDA staff: Jazz drug works, risk plan an issue
By Lisa Richwine
WASHINGTON | Wed Aug 18, 2010 11:23am EDT
(Reuters) - U.S. drug reviewers said a Jazz Pharmaceuticals Inc medicine helped patients with the pain disorder fibromyalgia, sending shares up 14 percent Wednesday on hopes an approval could sharply boost the company's sales.
Food and Drug Administration staff said the drug, sodium oxybate or JZP-6, was effective. But they also questioned if the company's proposed safeguards would adequately prevent improper use. The medicine contains an ingredient notoriously abused as a "date rape" drug.
Labels:
FDA Recommendation,
Food and Drug Administration,
Gamma-Hydroxybutyric acid,
Jazz,
Jazz Pharmaceutical,
Jazz Pharmaceuticals,
Narcolepsy,
Xyrem
Subscribe to:
Posts (Atom)